Dr. Hogan will lead APDN's drive to build its business in pharmaceuticals anti-counterfeiting, to form business relationships with biotech and healthcare customers, provide guidance to APDN's R&D efforts, and apply his considerable experience to development of APDN's in-field DNA analysis technology, among other responsibilities.
Dr. Hogan has 25 years of experience in translational science; breakthroughs in the use of DNA as therapeutics, as the basis for in vitro diagnostics, and the broad area of biospecimen stabilization have been particular areas of focus. He was an early pioneer in the development of lab-on-a-chip in his work as professor at
Dr. Hogan was awarded his Ph.D. with highest distinction by
As a researcher and entrepreneur in pharmaceuticals, Dr. Hogan has had extensive interaction with the
He holds 25 U.S. patents and many more international patents. He has considerable experience in managing large grant awards, directing as Principal Investigator large NIH, DoD,
Dr. Hogan commented, "
APDN is a provider of botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA describes the uncopyable marker that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of a family of products such as DNAnet®, our anti-theft product, SigNature® T, targeted toward textiles, and digitalDNA®, providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators.
The statements made by APDN may be forward-looking in nature. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's
Read the full story at http://www.prweb.com/releases/2014/07/prweb12054987.htm
Most Popular Stories
- Paniagua Wins Grand Prize in Young Artists Program
- Yaris Adds French Flair for US Market
- Cable TV Not Going Away, Says Cable TV
- German Intelligence Blames Ukraine Rebels for MH17
- IBM to Pay Big to Unload Chip Division
- Sub Hunt Brings Cold War Chill Back to Baltic
- Turkey to Help Kurds Reach Fight in Kobani
- Perez Leads Push for Obama's Job Proposals
- Cowboys Turn Back Clock to Glory Days
- Kerry Cites Moral Need in Weapons Air Drop